8-K: Guardant Health Reports Strong 2023 Revenue Growth, Provides Positive 2024 Outlook

Guardant Health's full year 2023 revenue increased by 25%, driven by a 39% growth in clinical test volume, and the company anticipates revenue between $655 to $670 million for 2024.

Summary

• Guardant Health reported a 25% increase in revenue for the full year 2023, reaching $563.9 million, compared to $449.5 million in 2022.
• Clinical test volume grew by 39% year-over-year, with 172,900 tests conducted in 2023.
• Biopharmaceutical test volume increased by 15% year-over-year, with 29,900 tests conducted in 2023.
• The company achieved cash flow breakeven in its Therapy Selection business by the end of 2023.
• For the fourth quarter of 2023, revenue was $155.1 million, a 22% increase compared to the same period in 2022.
• The company reported a net loss of $479.4 million for 2023, an improvement from the $654.6 million loss in 2022.
• Guardant Health expects full year 2024 revenue to be between $655 and $670 million, representing a 16% to 19% growth compared to 2023.
• Non-GAAP operating expenses for 2024 are projected to be between $740 and $750 million, a 1% to 3% increase compared to 2023.
• Free cash flow for 2024 is expected to be between negative $320 and $330 million, an improvement compared to 2023.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, increased clinical test volumes, and an improved outlook for 2024. The company's progress with its Shield test and cash flow breakeven in the Therapy Selection business further contribute to the positive sentiment. However, the net loss and decrease in gross margin temper the overall sentiment slightly.

Positives

• Guardant Health experienced strong revenue growth of 25% in 2023.
• Clinical test volumes saw a significant increase of 39% in 2023.
• The company achieved cash flow breakeven in its Therapy Selection business by the end of 2023.
• The company is projecting continued revenue growth in 2024, with an expected increase of 16% to 19%.
• Free cash flow is expected to improve in 2024 compared to 2023.
• The company has a strong cash position with $1.2 billion in cash, cash equivalents, and marketable debt securities.
• The ASP for Guardant360 LDT CMS reimbursement increased, which will positively impact future revenue.
• The company has made progress with the FDA on its PMA submission for Shield and anticipates an Advisory Committee Panel review.

Negatives

• The company reported a net loss of $479.4 million for 2023, although this is an improvement from the $654.6 million loss in 2022.
• Gross margin decreased from 65% in 2022 to 60% in 2023, primarily due to changes in product mix.
• Development services and other revenue decreased by 14% in 2023.
• The company incurred a non-recurring legal accrual of $83.4 million in 2023.
• The company's free cash flow was negative $345.5 million for 2023.

Risks

• The company's future results are subject to risks and uncertainties, including regulatory approvals and market acceptance of its products.
• The company's actual results could differ materially from the anticipated results and expectations expressed in forward-looking statements.
• The company is subject to risks and uncertainties discussed in its Annual Report on Form 10-K and other filings with the SEC.
• The company's ability to achieve its revenue and profitability targets depends on various factors, including market conditions and competition.

Future Outlook

Guardant Health anticipates continued growth in 2024, with revenue expected to be between $655 and $670 million, and an improvement in free cash flow. The company is also preparing to launch its Shield IVD test following expected FDA approval.

Management Comments

• Helmy Eltoukhy, co-founder and co-CEO, stated that 2023 was a strong year for Guardant, underscored by exceptional execution and strong clinical volumes.
• Helmy Eltoukhy also mentioned that the company surpassed an important milestone by achieving cash flow breakeven in its Therapy Selection business by year-end.
• AmirAli Talasaz, co-founder and co-CEO, noted that the company is making steady progress with the FDA on its PMA submission for Shield.
• AmirAli Talasaz also stated that 2024 will be a pivotal year for the screening business as they prepare to launch the Shield IVD test following expected FDA approval.

Industry Context

This announcement reflects the growing importance of precision oncology and liquid biopsy in cancer care. Guardant Health's focus on early cancer detection and therapy selection aligns with industry trends towards personalized medicine and improved patient outcomes. The company's progress with its Shield test is particularly relevant given the increasing emphasis on early cancer screening.

Comparison to Industry Standards

• Guardant Health's 25% revenue growth in 2023 is strong compared to some of its peers in the diagnostics industry, such as Exact Sciences, which reported a 20% revenue growth in 2023.
• The 39% increase in clinical test volume is also notable, indicating strong market adoption of their products.
• However, the company's net loss of $479.4 million highlights the challenges of achieving profitability in the competitive diagnostics market, similar to other companies in the space that are investing heavily in R&D and market expansion.
• The increase in ASP for Guardant360 LDT CMS reimbursement from $3,500 to $5,000 is a positive development, potentially improving revenue per test, which is a key metric for diagnostics companies.
• The company's focus on liquid biopsy and early cancer detection positions it well in the market, as these areas are expected to see significant growth in the coming years, similar to other companies like Grail and Freenome.

Management Changes

Legal Proceedings

• The company incurred a non-recurring legal accrual of $83.4 million in 2023.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved outlook positively.
• Employees may be encouraged by the company's progress and future prospects.
• Customers will benefit from the company's continued innovation in cancer diagnostics.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's improved financial performance favorably.

Next Steps

• The company will continue to work with the FDA on its PMA submission for Shield.
• The company is preparing to launch its Shield IVD test following expected FDA approval.
• The company will host a conference call to discuss the fourth quarter and full year 2023 financial results on February 22, 2024.

Key Dates

Keywords

precision oncology, liquid biopsy, cancer screening, genomic testing, Guardant360, Shield, biomarker testing, revenue growth, clinical volume, FDA approval